Moxifloxacin: update and perspectives after 8 years of usage.
Moxifloxacin has a broad spectrum of activity, including Gram-positive and Gram-negative organisms, atypical respiratory pathogens, anaerobes and penicillin- and macrolide-resistant Streptococcus pneumoniae. It achieves good tissue penetration and high concentrations in clinically relevant tissues and fluids. It is available in both an oral and intravenous formulation, has a once-daily administration and a good tolerance and safety profile. Moxifloxacin is used mainly for the treatment of acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, acute bacterial sinusitis, complicated skin and skin-structure infections and complicated intra-abdominal infections, as well as pulmonary TB, although it is not approved in this indication. The most recent studies covering these clinical indications are discussed.
Lode
Hartmut M
HM
RCMS Institute for Clinical Pharmacology, Charitè - Universitätsmedizin Berlin, Hohenzollerndamm 2, D10717 Berlin, Germany. haloheck@zedat.fu-berlin.de
Schmidt-Ioanas
Malina
M